A promising chromone-based compounds in drug discovery for new anti-inflammatory and anti-cancer drugs

Rullah, Kamal and Shamsudin, Nur Farisya (2022) A promising chromone-based compounds in drug discovery for new anti-inflammatory and anti-cancer drugs. In: International Conference on Contemporary Science and Clinical Pharmacy (ICCSCP) 2022, 26-27 October 2022, Padang-Indonesia. (Unpublished)

Preview	PDF - Cover Image Download (935kB) | Preview
Preview	PDF - Published Version Download (49kB) | Preview
Preview	PDF - Supplemental Material Download (335kB) | Preview
	PDF - Presentation Restricted to Repository staff only Download (4MB) | Request a copy

Abstract

Chromone, a group of heterocyclic compounds, has been recognised as a privileged structure for new drug discovery and development. These scaffolds have exhibited extensive acceptability due to their drug-like properties and versatile binding properties. Among several approved anti-inflammatory and anti-cancer drugs, these scaffolds show high selectivity for certain specific targets. For this reason, a significantly increasing number of research groups are interested in developing new synthetic methods and evaluating biological properties. In this view, we will discuss some of the important discoveries of chromone-based compounds as anti-inflammatory and anti-cancer agents, such as 2-(3,4-dimethoxyphenyl)-3-(4- fluorophenyl)-6-methoxy-4H-chromen-4-one (KR-1401-KW) which was found to be significantly active in suppressing PGE2-associated inflammatory responses and 3-(4-(chloromethyl)phenyl)-2-(3,4- dimethoxyphenyl)-7-methoxy-4H-chromen-4-one which was displayed potential inhibitor of UNC-51-like kinase 1 (ULK1) (KR-2201-NF) modulates autophagy and induces apoptosis in colon cancer. Moreover, computational evidence, including docking and molecular dynamics (MD) simulations, makes the compounds promising candidates for new anti-inflammatory and anti-cancer drugs.

Item Type:	Conference or Workshop Item (Invited Papers)
Uncontrolled Keywords:	chromone; anti-inflammation; anti-cancer; docking study; molecular dynamics (MD) simulations
Subjects:	R Medicine > RS Pharmacy and materia medica > RS403 Materia Medica-Pharmaceutical Chemistry
Kulliyyahs/Centres/Divisions/Institutes (Can select more than one option. Press CONTROL button):	Kulliyyah of Pharmacy > Department of Pharmaceutical Chemistry
Depositing User:	Dr Kamal Rullah
Date Deposited:	26 Dec 2022 15:17
Last Modified:	17 Jan 2023 16:34
URI:	http://irep.iium.edu.my/id/eprint/102004

Actions (login required)

View Item